Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Go back to Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 33.38 -0.3 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.68 | 52 Week High | $5.17 | |||
| Open | $33.36 | 52 Week Low | $0.94 | |||
| Day High | $34.60 | P/E | N/A | |||
| Day Low | $33.30 | EPS | $0.00 | |||
| Volume | 442,453 | |||||
